iPSC-derived mesenchymal cells that support alveolar organoid development

Graphical abstract

Authors
Koji Tamai, Kouji Sakai, Haruka Yamaki, ..., Masatoshi Hagiwara, Toyouhiro Hirai, Shimpei Gotoh

Correspondence
gotoh.shimpei.5m@kyoto-u.ac.jp

In brief
Tamai et al. develop a method for generating iPSC-derived mesenchymal cells (iMESs) capable of developing alveolar organoids (iMES-AOs). iMESs can induce not only alveolar epithelial type II but also type I cells. iMES-AOs provide a platform for modeling lung development and diseases including respiratory viral infection.

Highlights
- We report a method for generating iPSC-derived mesenchymal cells (iMESs)
- iMESs induce development of alveolar organoids without the use of allogenic fetal cells
- iMES-alveolar organoids enable studies of the niche environment and pulmonary diseases
iPSC-derived mesenchymal cells that support alveolar organoid development

Koji Tamai,1 Kouji Sakai,2,3 Haruka Yamaki,1 Keita Moriguchi,4 Koichi Igura,1 Shotaro Maehana,5,6,7 Takahiro Suezawa,4 Kazuaki Takehara,8,9 Masatoshi Hagiwara,10 Toyohiro Hirai,1 and Shimpei Gotoh1,4,11,12,*

1Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
2Department of Veterinary Science, National Institute of Infectious Diseases, Tokyo, Japan
3Department of Virology 3, National Institute of Infectious Diseases, Tokyo, Japan
4Department of Drug Discovery for Lung Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan
5Department of Environmental Microbiology, Graduate School of Medical Sciences, Kitasato University, Kanagawa, Japan
6Department of Microbiology, School of Allied Health Sciences, Kitasato University, Kanagawa, Japan
7Regenerative Medicine and Cell Design Research Facility, Kanagawa, Japan
8Laboratory of Animal Health, Department of Veterinary Medicine, Faculty of Agriculture, Tokyo University of Agriculture and Technology, Tokyo, Japan
9Laboratory of Animal Health, Cooperative Division of Veterinary Science, Graduate School of Agriculture, Tokyo University of Agriculture and Technology, Tokyo, Japan
10Department of Anatomy and Developmental Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan
11Center for IPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan
12Lead contact
*Correspondence: gotoh.shimpei.5m@kyoto-u.ac.jp
https://doi.org/10.1016/j.crmeth.2022.100314

SUMMARY

Mesenchymal cells are necessary for organ development. In the lung, distal tip fibroblasts contribute to alveolar and airway epithelial cell differentiation and homeostasis. Here, we report a method for generating human induced pluripotent stem cell (iPSC)-derived mesenchymal cells (iMESs) that can induce human iPSC-derived alveolar and airway epithelial lineages in organoids via epithelial-mesenchymal interaction, without the use of allogenic fetal lung fibroblasts. Through a transcriptome comparison of dermal and lung fibroblasts with their corresponding reprogrammed iPSC-derived iMESs, we found that iMESs had features of lung mesenchyme with the potential to induce alveolar type 2 (AT2) cells. Particularly, RSPO2 and RSPO3 expressed in iMESs directly contributed to AT2 cell induction during organoid formation. We demonstrated that the total iPSC-derived alveolar organoids were useful for characterizing responses to the influenza A (H1N1) virus and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, demonstrating their utility for disease modeling.

INTRODUCTION

Mesenchymal cells provide extracellular matrix proteins and various secreted proteins suited to cell-type-specific tissue microenvironments, and their interaction with epithelial cells is essential for normal organ development, homeostasis, and regeneration. Previous studies have described human pluripotent stem cell (PSC)-derived alveolar epithelial cells in both a fibroblast-dependent (Gotoh et al., 2014; Yamamoto et al., 2017) and a fibroblast-free procedure (Jacob et al., 2017; Yamamoto et al., 2017). Challenges to simultaneous differentiation of lung epithelial and mesenchymal cells have been reported (Chen et al., 2017; Dye et al., 2015; Miller et al., 2019), but the process of deriving mesenchymal cells from PSCs remains unknown. Given the potential application of the PSC-derived alveolar organoid (AO) for research in human developmental...

Motivation

Organoid technology is a powerful tool for bioscience research. Previously, human fetal lung fibroblasts (HFLFs) have been used to promote the development of alveolar organoids, but HFLFs have the limitation of being allogenic in organoid systems, and therefore they cannot reproduce an individual’s biological environment. To address this limitation, we generated induced pluripotent stem cell-derived mesenchymal cells (iMESs) that have the ability to develop alveolar organoids with the aim of modeling niche environments and diseases.
**Cell Reports Methods**

**Report**

(A) NKX2-1+ lung progenitors sorted by CPM

(B) Day 0 iPSCs → Day 3 Mesoderm → Day 7 Mesenchyme → Day 21 IMES dependent alveolar organoids

(C) Images showing cell growth over time.

(D) Flow cytometry data showing cell populations at different time points.

(E) Immunofluorescence images of E-cadherin, VIM, FOXF1.

(F) Comparison of non-reporter and SFTPC-GFP reporter cell populations.

(G) Graph showing SFTPC-GFP/EPICAM expression.

(H) Heatmaps of gene expression for different conditions.

(I) Scatter plot showing expression levels of different factors.

(legend on next page)
processes and disease modeling, AOs should include mesenchymal cells. Primary human fetal lung fibroblasts (HFLFs) have been used, but it is often difficult to recapitulate the exact biological environment found in the lung. Although others have reported human PSC-derived lung mesenchymal cells that recapitulated the developmental course of mouse early fetal foregut organogenesis (Han et al., 2020; Kishimoto et al., 2020), AO formation using PSC-derived lung mesenchymal cells has not been accomplished. Hence, it is desirable to generate mesenchymal cells that can support organ development and facilitate further research in embryonic organogenesis.

In this study, we report a method for generating human induced PSC (iPSC)-derived mesenchymal cells (iMESs) that are able to form AOs (iMES-AOs). We also explored niche factors to induce iPSC-derived alveolar type 2 (iAT2) cells from progenitor cells using transcriptomic analysis of paired isogenic iMESs and the mesenchymal cells of primary fibroblasts. Moreover, we used iMES-AOs in two pandemic respiratory infection models, the influenza A (H1N1) virus and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

RESULTS

Generation of mesenchymal cells that induce iAT2 cells

We optimized a method to differentiate mesenchymal cells that were able to induce SFTPC+ iAT2 lineage cells from their progenitor cells (Figures 1A and 1B). AOs were generated in a three-dimensional (3D) co-culture of SFTPC-GFP reporter iPSC (B2-3)-derived NKK2-1 lung progenitors sorted by carboxypeptidase M (CPM) and iMESs derived from their parental 201B7 iPSC line (201B7-iMESs). First, we focused on mesoderm induction followed by differentiation of mesenchymal cells. On day 1, cell clusters started to lose their border sharpness in a medium containing activin A, BMP4, and CHIR99021, and they appeared as primitive streak-like cells expressing T-box T in the EPCAM+ cell population (Figures 1C and 1D). Cells became oblong in shape on day 3, and the EPCAM+ cell population became positive for the mesodermal markers NCAM, PDGF-Rα, and KDR (Evseenko et al., 2010; Sakurai et al., 2006). A new medium containing activin A, KGF, BMP4, FGFR2, and FGF10 induced the expression of VIM, THY1, PDGF-Rα, and KDR on day 7. Because a minor EPCAM+ cell population showed insufficient mesenchymal marker expression (Figure 1D), we purified EPCAM+ cells and named them “iMESs.” Time course changes of each marker were validated using qRT-PCR, and gene expression levels were compared among iMESs, HFLFs, and human dermal fibroblasts (HDFs) (Figure S1A). iMESs also expressed FOXF1 and TBX4 as lung mesenchymal markers (Han et al., 2020; Horie et al., 2018) (Figures 1E and S1A).

3D co-culture of lung progenitors derived from B2-3 line and 201B7-iMESs produced spheroids that included SFTPC-GFP+ iAT2 cells (Figure S1B). Quantitative analysis using flow cytometry validated the SFTPC-GFP+/EPCAM+ iAT2 cell ratio in co-culture with HFLFs, 201B7-iMESs, and iMESs derived from another healthy donor-derived iPSC line (604A1) (Figures 1F and 1G). HDFs did not form spheroids and had fewer SFTPC-GFP+/EPCAM+ cells. We found that activin A, KGF, BMP4, FGFR2, and FGFR10 all affected iMESs and contributed to the induction of SFTPC-GFP+/EPCAM+ iAT2 cells. Each single factor was removed from the medium between days 3 and 7; AOs were produced with lung progenitors derived from B2-3 line and 201B7-iMESs, followed by quantification of the SFTPC-GFP+/EPCAM+ iAT2 cell ratio. iMESs treated with all factors induced the highest SFTPC-GFP+/EPCAM+ iAT2 cell ratio (Figures 1H and 1I). Immunofluorescence staining of iMES-AO samples showed that VIM+iMESs spread throughout the spheroids. AT2 cell markers ProSPC, ABCA3, SFTPC-GFP, and mature-SPC were detected in the cuboidal cells. PDNP+/HT1-56+ thin-shaped cells were also observed, indicating the presence of iAT1 cells in the spheroids (Dobbs et al., 1999) (Figure S1C). AT1 and AT2 markers were detected in iMES-AOs using qRT-PCR (Figure S1D).

Generation of iMESs from HFL- and HDF-derived iPSCs to form AOs

To elucidate the role of iMESs in inducing iAT2 cells, we compared primary fibroblasts with iMESs. Because HDFs cannot generate AOs, we can eliminate unnecessary factors for AO development. We generated iPSCs from HFLFs and HDFs (HFLF-iPSCs and HDF-iPSCs, respectively) that presented expression of undifferentiated markers, normal karyotypes, and trilineage-differentiation potentials (Figures S2A and S2B). Both pre- and post-3D culture samples of HFLFs, HDFs, and their iMESs were recovered (Figure 2A). FOXF1 was highly expressed in HFLFs and each iMES but was weak in HDFs (Figure 2B). The ability to induce SFTPC-GFP+/EPCAM+ iAT2 cells was verified in both HFLF- and HDF-iMESs (Figures 2C and 2D).

iMESs and HFLFs, but not HDFs, express genes associated with lung development

Principal-component analysis of RNA sequencing (RNA-seq) transcriptomes revealed well-separated clusters of each condition. Post-3D culture iMES and HFLF transcriptomes were both...
similar to one another and dissimilar to post-3D culture HDFs, inferred from the relative plot distance between populations (Figure 2E). Selected lineage gene markers for fibroblast, muscle, adipocyte, endothelial, and immune cells were depicted on a heatmap in columns scaled to transcripts per million (TPM). The expression levels of fibroblast markers were considerably high, indicating that iMESs share transcriptomic programs similar to fibroblasts (Figure 2F). Furthermore, we evaluated respiratory mesenchymal markers, including WNT2, TCF21, FOXF1, NKX6-1, and PRRX1 (Goss et al., 2009; Han et al., 2020; Kishimoto et al., 2020; Park et al., 2019; Yeo et al., 2018) (Figure 2G). Post-3D culture HFLFs showed the highest expression of WNT2, followed by pre-3D culture HFLFs and HDFs, but HFLF-iMESs, HDF-iMESs, and post-3D HDFs expressed WNT2 at extremely low levels. Although expression levels of TCF21 and FOXF1 were also highest in post-3D culture HFLFs, they were also prominent in post-3D culture HFLF- and HDF-iMESs. NKX6-1 was barely detected in any of the samples, and PRRX1 was highest in HDFs, followed by HFLFs. Gene Ontology (GO) enrichment analysis of biological processes indicated that “embryonic organ development” and “lung development” were significantly enriched in both up- and down-regulated differentially expressed genes (DEGs) between HDF-iMESs and HDFs (Figure 2H). DEGs annotated to “lung development” were illustrated in a heatmap using four groups of mesenchymal transcriptomes (Figure 2I). Although WNT5A, FGFR7, and PDGFRA are important factors in AT2 cells (Barkauskas et al., 2013; Nabhan et al., 2018; Zepp et al., 2017), they were up-regulated in HDFs. Secreted factors, including RSPO2, WNT11, CCN2, SPARC, BMP4, HHIP, LAMAX, and LOX were up-regulated in iMESs. Expression levels of transcription factors, including FOXF1 and TCF21, were higher in HFLF- and HDF-iMESs and HFLFs than in HDFs, suggesting that iMESs share features of fetal lung fibroblasts. HFLF-iMESs and HFLFs shared expression of EAPAS1, yet HFLFs expressed EAPAS1 at higher levels than HFLFs, which indicates that EAPAS1 is not specific to the lung mesenchyme (Figure 2I). Next, we compared the top 5,000 genes of post-3D culture HFLF-iMESs and HFLFs in a Venn diagram (Figure 2J). There were 4,220 common genes, of which “lung development” was enriched (false discovery rate [FDR] q = 0.001). Genes annotated to “lung development” included HHIP, CCN2, SPARC, BMP4, LAMAX, and LOX, suggesting that they were important factors for AO generation. Further, the transcription factors FOXF1 and TCF21 were included, and they may be potential markers for lung fibroblasts.

**iMESs expressing high levels of RSPO2 and RSPO3 directly contributed to iAT2 cell induction**

We conducted a validation study using fibroblast-free AOs to determine the presence of candidate cytokines in the RNA-seq analysis data. We previously reported that combining the two inhibitors CHIR99021 and SB431542 (2i) contributed to iAT2 cell induction in a fibroblast-free manner (Yamamoto et al., 2017), and we hypothesized that Wnt ligands and antagonists of transforming growth factor β (TGF-β) family ligands increased in iMESs could substitute for 2i. Because only Wnt/β-catenin seemed important for AT2 cell differentiation (Aros et al., 2021; Frank et al., 2016; Shu et al., 2005), highly expressed canonical Wnt ligands and antagonists of TGF-β family ligands were selected, but WNT5A, WNT5B, and WNT11, which are associated with the non-canonical Wnt signaling pathway, were excluded (Table S3) (Cohen et al., 2012; Hardy et al., 2008; Mikels and Nusse, 2006). HDFs did not contain any canonical Wnt ligands transcribed in the defined list (Table S3). We noted that RSPO2 and RSPO3 transcript levels were higher in HFLF- and HDF-iMESs and HFLFs than in HDFs. To test the ability of these candidates to produce AOs in a fibroblast-free environment, we incubated cells in a medium supplemented with CHIR99021/SB431542 (2i), RSPO2/SB431542, RSPO3/SB431542, RSPO2/RSPO3, or RSPO2/RSPO3/SB431542 (Figure S2C). RSPO2/RSPO3/SB431542 increased the SFTPC-GFP+/EPCAM+ iAT2 cell ratio to a level comparable to that of 2i (Figures S2D and S2E). Next, we selected candidate endogenous genes of TGF-β-ligand antagonists to replace SB431542 (Table S3). We noted that FST, FSTL1, FSTL3, and DCN had high enough TPM values in iMESs to test despite lower expression levels in both HFLF- and HDF-iMESs than in post-3D culture HDFs. Fibroblast-free AOs were formed in a medium supplemented with RSPO2/RSPO3/SB431542, RSPO2/RSPO3/FST, RSPO2/RSPO3/FSTL1, RSPO2/RSPO3/FSTL3, RSPO2/RSPO3/DCN, RSPO2/RSPO3/3F (FST/FSTL1/FSTL3), and RSPO2/RSPO3/4F (FST/FSTL1/FSTL3/DCN). However, the SFTPC-GFP+/EPCAM+ iAT2 cell ratio did not increase with any factor supplementation (Figures S2F and S2G).

**Figure 2.** Generation of iPSCs from HFLFs and HDFs to compare the difference between iMESs and their original human primary fibroblasts (A) Strategy for pairwise isogenic comparison among HFLFs and HDFs (TIG120), and iMESs derived from iPSCs generated from each fibroblast. (B) Immunofluorescence staining of E-Cadherin, VIM, and FOXF1. Scale bars, 100 µm. (C and D) Flow cytometry data of the induction efficiency of SFTPC-GFP+/EPCAM+ cells and its quantification. iMESs were differentiated from HFLF-iPSCs (HFA) and HDF-iPSCs (GC23). The SFTPC-GFP reporter iPSC line (B2-3) was differentiated to lung progenitors. Data are presented as mean ± SEM. “p < 0.01 (Dunnett’s post hoc test). (E) Principal-component analysis of RNA-seq transcriptomes of iMESs, HFLFs, and HDFs in each condition. (F) Heatmap of non-epithelial lineage marker genes. (G) Heatmap of selected respiratory mesenchymal markers. The numbers in cells are mean read counts of 3 replicates. (H) GO analysis of DEGs between HDF-iMESs versus HDFs in pre-3D culture conditions. Representative GOs of biological processes in up-regulated (log2 fold change [FC] > 1, FDR < 0.05) and down-regulated DEGs (log2FC < −1, FDR < 0.05) are shown. (I) Heatmap of DEGs annotated to “lung development.” DEGs with a maximum average TPM of 3 replicates >20 between HDF-iMESs and HDFs in post-3D culture conditions were selected. Red and blue in the left side bar show up-regulated and down-regulated DEGs, respectively. (J) Common genes among the top 5,000 genes of HFLF-iMESs and HFLFs in post-3D culture conditions. Up-regulated transcription factors and secreted proteins annotated to “lung development” out of 4,220 genes in common are listed. Red colored genes indicate up-regulated genes in (I) as well. See also Figure S2.
iMESs expanded iAT2 cells by repeated passages
We performed passage culture of SFTPC+/EPCAM+ iAT2 cells with newly differentiated iMESs prepared for each passage (Figure 3A). The cumulative population doubling level (PDL) of EPCAM+ cells increased linearly (Figure 3B). The SFTPC+/EPCAM+ iAT2 cell ratio immediately increased after a single passage, and it significantly increased from passage 0 (P0) to P2 (p = 0.002) (Figures 3C and 3D). qRT-PCR showed that ABCA3 and SLC34A2 (AT2 markers) and HOPX (AT1 marker) significantly increased from P0 to P3 (Figure S3A). Expression of other alveolar lineage markers, SFTPB, SFTPD2, SFTPA2, AGER, and AQP5, were maintained during the passages. Immunofluorescence (IF) staining showed both SFTPC-GFP+ iAT2 and PDPN+/HT1-56+ iAT1 cells in P2-AOs (Figure 3E). We used transmission electron microscopy to visualize the lamellar bodies and specific structures of AT2 cells (Figure 3F).

scRNA-seq analysis revealed multiple cell types in iMES-AOs and HFLF-AOs
We performed single-cell RNA-seq (scRNA-seq) to compare iMES-AOs (derived from B2-3 lung progenitors and 201B7-iPSCs) with HFLF-AOs (derived from B2-3 lung progenitors and HFLFs) at both P0 and P2. Epithelial and mesenchymal cells were segregated by expressing high levels of EPCAM and COL1A1, respectively, and clusters of mitotic cells expressing MKI67 and TOP2A were also identified in both types of cells (Figures 3G–3I). Non-mitotic epithelial cells were re-clustered and annotated based on enriched gene expression profiles. iAT1, iAT2, iPSC-derived ciliary cells (iCilias), iPSC-derived pulmonary neuroendocrine cells (iPNECs), ASCL1+ clusters, and TM4SF1+ clusters were identified (Figures 3J and S3B). iMESs and HFLFs seemed to have different inductive abilities because iAT2 and iCilia were more numerous in iMES-AOs, especially since iCilia was seen only in iMES-AOs at P2 (Figures 3K and 3L). Conversely, iAT1, iPNEC, and ASCL1+ cells were more numerous in HFLF-AOs. However, expression levels of AT1, AT2, and PNEC markers in each cluster tended to be higher in iMES-AOs than in HFLF-AOs (Figure 3M). TM4SF1+ cells were more abundant in iMES-AOs at P2 (Figures 3K and 3L). iMESs without mitotic cells were separated into five clusters: FOXF1+TCF21+, ACTA2+FOXF1+TCF21+, PRRX1+FOXF1+TCF21+, CXCL12+FOXF1+TCF21+, and IRX3+FOXO1+TCF21+FOXF1 (Figure 3N). The representative genes were depicted on violin plots (Figure S3C). TCF21 was expressed in all clusters, while FOXF1 was expressed in all but the IRX3+FOXO1+TCF21+FOXF1 cluster. CXCL12+FOXF1+TCF21+ cells were abundant in iMES-AOs, and WT1 was exclusively expressed in iMESs. The IRX3+FOXO1+TCF21+FOXF1 cluster consisted almost entirely of iMESs (Figures 3O and 3P). RSP02 was expressed considerably more in iPNECs, and RSPO3 was expressed in both HFLFs and iMESs (Figure S3C). WNT2, CHFRC1, and MYH11 were almost exclusively expressed in HFLFs. ACTA2+MYH11+ mature myogenic cells were mostly seen in HFLFs.

H1N1 and SARS-CoV-2 infection of iMES-AOs induce intrinsic interferon responses
We applied iMES-AOs to disease modeling of acute respiratory viral infections. iMES-AOs (P2) on day 12 were infected with H1N1 or SARS-CoV-2 for 3 days and then collected for analysis (Figure 4A). The viral titer was higher in H1N1-infected iMES-AOs than in the no-cell control (6.1 ± 0.1 versus 2.6 ± 0.1, log_{10}PFU/mL) (Figure 4B). The nucleoprotein of H1N1 was detected in EPCAM+ epithelial cells, and some infected cells, including SFTPC-GFP+ iAT2 cells, fell into the lumen (Figure 4C). We observed MX1+ cells, showing a type I interferon response induced by H1N1 infection (Figure 4D). In contrast, the nucleocapsid protein of SARS-CoV-2 was not stained in SARS-CoV-2-infected iMES-AOs. We speculated that inaccessibility to the apical inside of AOs interfered with the efficient infection of SARS-CoV-2, while H1N1 could invade AOs from the basolateral side, where sialic acid is present. Thus, we dissociated whole gels of iMES-AOs and then incubated the gels in a viral solution of SARS-CoV-2 for 2 h, as described previously (Mulay et al., 2021). After washing, they were re-cultured in a 3D culture with Matrigel (Figure 4E). Three days later, the viral titer increased compared with both the no-cell control and the previous non-dissociated samples (3.2 ± 0.2 versus 4.5 ± 0.2 versus 5.7 ± 0.1, log_{10}PFU/mL) (Figure 4F), suggesting that the virus could approach the apical side of organoids where abundant receptors are present. The nucleocapsid protein of SARS-CoV-2 was also seen in i MES-AOs.
(legend on next page)
detected (Figure 4G). NaPi2b and the nucleocapsid protein were co-stained, indicating infected AT2 cells (Figure 4H), and MX1+ cells indicated that the type I interferon response was induced by SARS-CoV-2 infection (Figure 4I).

**DISCUSSION**

In this study, we featured iMESs that efficiently induced SFTPC-GFP+/EPCAM+ iAT2 cells via epithelial-mesenchymal interactions. Although the iMES transcriptome did not completely match that of HFLFs, our approach to generate human PSC-derived mesenchymal cells that are suited for inducing tissue epithelial cells, such as iAT1 and iAT2 cells, might inform us of the most crucial factors in organogenesis.

Previous studies have reported a method of induction of respiratory mesenchymal cells (Han et al., 2020; Kishimoto et al., 2020). In these studies, NKX6-1 was induced as a respiratory mesenchymal marker with retinoic acid, BMP4, and Hedgehog agonists, followed by a low-dose WNT agonist. Intriguingly, although iMESs do not express NKX6-1, we succeeded in expressing SFTPC-GFP in alveolar epithelial cells in iMES-AOs. Indeed, we observed a low NKX6-1 expression level, even in HFLFs; thus, we speculated that NKX6-1 might not be requisite for inducing AOs. Moreover, a recent study reported the differentiation of mouse PSC-derived lung-specific mesenchymal cells via Tbx4+ state (Alber et al., 2022). Although AT1/AT2 markers, including Sftpc, Ager, and Hopx, were not robustly induced in the study, it was demonstrated that lung progenitor cells expressed early distal lung epithelial markers, such as Sox9 and Etv5, indicating insufficient inducing factors of AT1/AT2 cells. iMES transcriptome analysis and subsequent validation revealed that RSPO2 and RSPO3 expressed in iMESs could promote iAT2 cell induction. This is consistent with a recent report that revealed that RSPO2+ mesenchymal cells were adjacent to human fetal lung bud tip progenitors and that RSPO2 might potentially possess a pivotal role in proximal-distal patterning (Hein et al., 2022). The low expression level of WNT2 was unexpected because Wnt2/2b signaling has been reported to be essential for lung endoderm specification (Goss et al., 2009). However, RSPO2/RSPO3 expressed in iMESs could promote iAT2 cell induction, substituting for the WNT2 expressed in HFLFs for activation of canonical WNT signaling. The lack of canonical WNT ligand gene expression in HDFs might be one reason for their inability to induce iAT2 cells. On the other hand, it was an unexpected result that WNT5A, FGFR7, and PDGFRα, known to be important factors in AT2 cells (Barkauskas et al., 2013; Nabhan et al., 2018; Zepp et al., 2017), appeared to be up-regulated in HDFs, compared with iMESs and HFLFs, although FGFR7 was supplemented in the alveolarization medium. In a previous study, we reported that AOs could not develop without mesenchymal cells if CHIR99021, SB431542, and Y27632 were not added (Yamamoto et al., 2017). Therefore, there should be cell-cell interactions between iMESs and alveolar epithelial cells that at least complement the role of SB431542. All in all, further studies are needed to clarify AT2 cell induction downstream pathways. We also elucidated that iMES-AOs and HFLF-AOs included multiple cell types using scRNA-seq transcriptomics. Expression levels of each lineage marker tended to be higher in iMES-AOs, suggesting that iMESs could induce more mature respiratory epithelial cells compared with HFLFs. FOXJ1+/RSPH1+ iCilia observed in iMES-AOs at P2 co-expressed SFTPC; hence, they may be cells that would differentiate to mature multiciliated cells from SFTPC+ distal tip cells. TM4SF1+ cells were numerous in iMES-AOs at P2. TM4SF1 has been noted as a marker of Wnt-responsive alveolar epithelial progenitor lineage (Zacharias et al., 2018), and further verification is needed on whether TM4SF1+ cells in iMES-AOs could serve as progenitors. In the analysis of mesenchymal cells, the IRX3+FOXO1+TCF21+ FOXF1+ cluster and the CXCL12+FOX1+TCF21+ cluster were distinctive in iMESs. Further studies are needed to determine if these clusters have the power to induce respiratory epithelial cells, particularly iCilia that could be induced by iMESs but not by HFLFs.

In conclusion, iMES-AOs may be used to investigate the central mechanism of alveolar differentiation through epithelial-mesenchymal interactions, which would be helpful for disease models, drug screening, and niche reconstruction for in vivo lung regeneration in the future.

**Limitations of the study**

It is advantageous that the ratio of SFTPC-GFP+/EPCAM+ cells increased until P3 in iMES-AOs, but in this study, we did not validate the phenotypes of iMES-AOs in long-term passages. We applied the iMES-AO platform to the H1N1 and SARS-CoV-2 infection models, and iMES-AOs were analyzed at 72 h post-infection because the highest viral titers were observed in the...
STAR METHODS

Detailed methods are provided in the online version of this paper and include the following:

- **KEY RESOURCES TABLE**
- **RESOURCE AVAILABILITY**
  - Lead contact
  - Materials availability
  - Data and code availability
- **EXPERIMENTAL MODEL AND SUBJECT DETAILS**
  - Generation of human iPSCs
  - Maintenance of iPSCs
- **METHOD DETAILS**
  - Induction of IMES
  - Induction of NKX2-1+ lung progenitor cells
  - AOs formation in a 3D culture and passage of SFTPC+ cells
  - Validation study of canonical Wnt ligands and TGFβ-inhibitors using fibroblast-free AOs
  - Viruses
  - Direct infection of influenza A and SARS-CoV-2 viruses of matrigel-embedded organoids
  - SARS-CoV-2 WK-521 infection post organoid dissociation
  - Flow cytometry
  - RNA-seq analysis
  - scRNA-seq analysis
  - qRT-PCR
  - IF staining
  - Electron microscopy
- **QUANTIFICATION AND STATISTICAL ANALYSIS**

SUPPLEMENTAL INFORMATION

Supplemental information can be found online at https://doi.org/10.1016/j.crmeth.2022.100314.

ACKNOWLEDGMENTS

We thank S. Yamanaka, K. Woltjen, Y. Yoshida, T. Kawamura, and all the Fight Corona Project members at the Center for iPSC Cell Research and Application (CiRA), Kyoto University, and CiRA Foundation; H. Kitasato at Department of Environmental Microbiology, Kitasato University; and T. Noda at the Institute for Frontier Life and Medical Sciences, Kyoto University, for the helpful discussions and comments; S. Matsuo and Y. Maeda for assisting experimental procedures; and K. Okamoto-Furuta and H. Kohda (Division of Electron Microscopic Study, Center for Anatomical Studies, Kyoto University) for performing electron microscopy. This study was funded by JSPS Fellows (JP20J15105 to K.T.), Fujisawa Memorial Foundation, Japan (to K.T.), JSPS KAKENHI (JP18H02352 and JP21H02973 to K.S. and JP17H05084 and JP22K19525 to S.G.), AMED (JP20dk108270 to M.H., JP17bm0804007 to T.H., and JP19bm0704037 and JP22bm1123013 to S.G.), the COVID-19 Private Fund (to the Shinya Yamanaka laboratory, CiRA, Kyoto University, Japan), and in part by JST Core Research for Evolutional Science and Technology (JPMJCR20HA to Takeshi Noda and S.G.).

AUTHOR CONTRIBUTIONS

K.T. and S.G. conceived and designed the study and analyzed all the data throughout the manuscript. K.T. and H.Y. performed the experiments. K.T. and K.I. generated iPSCs. K.S. and S.M. performed the experiments and analyses on viral infections. K.M. and T.S. contributed to new reagents and analytical tools. K.T. and S.G. wrote the manuscript through fruitful discussions with K.S., K.M., T.S., K.T., M.H., T.H., and H.K.

DECLARATION OF INTERESTS

K.T. and S.G. are inventors of a patent application for generating iPSC-derived lung distal tip mesenchymal cells. S.G. is an inventor of Kyoto University’s patents for generating AOs. M.H. and S.G. are founders and shareholders of Hi-Lung, Inc. K.M. and T.S. were employees and shareholders of Kyorin Pharmaceutical Co., Ltd.

REFERENCES

Alber, A.B., Marquez, H.A., Ma, L., Kwong, G., Thapa, B.R., Villacorta-Martín, C., Lindstrom-Vautrin, J., Bawa, P., Luo, Y., Ikonomou, L., et al. (2022). Directed differentiation of mouse pluripotent stem cells into functional lung-specific mesenchyme. Preprint at bioRxiv. https://doi.org/10.1101/2022.08.12.502651.

Aros, C.J., Pantojia, C.J., and Gomperts, B.N. (2021). Wnt signaling in lung development, regeneration, and disease progression. Commun. Biol. 4, 601. https://doi.org/10.1038/s42003-021-02118-w.

Barkauskas, C.E., Cronce, M.J., Rackley, C.R., Bowie, E.J., Keene, D.R., Stripp, B.R., Randell, S.H., Noble, P.W., and Hogan, B.L.M. (2013). Type 2 alveolar cells are stem cells in adult lung. J. Clin. Invest. 123, 3025–3036. https://doi.org/10.1172/JCI68782.

Chen, S., Zhou, Y., Chen, Y., and Gu, J. (2018). fastp: an ultra-fast all-in-one FASTQ preprocessor. Bioinformatics 34, i884–i890. https://doi.org/10.1093/bioinformatics/bty560.

Chen, Y.W., Huang, S.X., de Carvalho, A.L.R.T., Ho, S.H., Islam, M.N., Volpi, S., Notarangelo, L.D., Ciancanelli, M., Casanova, J.L., Bhattacharya, J., et al. (2017). A three-dimensional model of human lung development and disease from pluripotent stem cells. Nat. Cell Biol. 19, 542–549. https://doi.org/10.1038/ncb3510.

Cohen, E.D., Miller, M.F., Wang, Z., Moon, R.T., and Morrissey, E.E. (2012). Wnt5a and Wnt11 are essential for second heart field progenitor development. Development 139, 1931–1940. https://doi.org/10.1242/dev.069377.

Dobbs, L.G., Gonzalez, R.F., Allen, L., and Froh, D.K. (1999). HT156, an integral membrane protein specific to human alveolar type I cells. J. Histochem. Cytochem. 47, 129–137. https://doi.org/10.1177/002215549904700202.

Dobin, A., Davis, C.A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., and Gingeras, T.R. (2013). STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15–21. https://doi.org/10.1093/bioinformatics/bts635.

Dye, B.R., Hill, D.R., Ferguson, M.A., Tsai, Y.H., Nagy, M.S., Dyal, R., Wells, J.M., Mayhew, C.N., Nattiv, R., Klein, O.D., et al. (2015). In vitro generation of human pluripotent stem cell derived lung organoids. Elife 4. https://doi.org/10.7554/eLife.05098.

Eveenko, D., Zhu, Y., Schenke-Layland, K., Kuo, J., Latour, B., Ge, S., Scholes, J., Dravid, G., Li, X., MacLellan, W.R., and Crooks, G.M. (2010). Mapping the first stages of mesoderm commitment during differentiation of human embryonic stem cells. Proc. Natl. Acad. Sci. USA 107, 13742–13747. https://doi.org/10.1073/pnas.1002077107.

Frank, D.B., Peng, T., Zepp, J.A., Smitow, M., Vincent, T.L., Penkala, I.J., Cui, Z., Herriges, M.J., Morley, M.P., Zhou, S., et al. (2016). Emergence of a wave of...
Wnt signaling that regulates lung alveologenesis by controlling epithelial self-renewal and differentiation. Cell Rep. 17, 2312–2325. https://doi.org/10.1016/j.celrep.2016.11.001.

Goss, A.M., Tian, Y., Tsukiyama, T., Cohen, E.D., Zhou, D., Lu, M.M., Yamaguchi, T.P., and Morrisey, E.E. (2009). Wnt2/βc and beta-catenin signaling are necessary and sufficient to specify lung progenitors in the foregut. Dev. Cell 17, 290–298. https://doi.org/10.1016/j.devcel.2009.06.005.

Gotoh, S., Ito, I., Nagasaki, T., Yamamoto, Y., Konishi, S., Korogi, Y., Matsumoto, H., Muro, S., Hirai, T., Funato, M., et al. (2014). Generation of alveolar epithelial spheroids via isolated progenitor cells from human pluripotent stem cells. Stem Cell Rep. 3, 394–403. https://doi.org/10.1016/j.stemcr.2014.07.005.

Han, L., Chaturvedi, P., Kishimoto, K., Koike, H., Nasr, T., Iwasawa, K., Giesbrecht, K., Wittcher, P.C., Eicher, A., Haines, L., et al. (2020). Single cell transcriptomics identifies a signaling network coordinating endoderm and mesoderm diversification during foregut organogenesis. Nat. Commun. 11, 4158. https://doi.org/10.1038/s41467-020-17968-x.

Hao, Y., Hao, S., Andersen-Nissen, E., Mauck, W.M., 3rd, Zheng, S., Butler, A., Lee, M.J., Wilik, A.J., Darby, C., Zaby, M., et al. (2021). Integrated analysis of multimodal single-cell data. Cell 184, 3573–3587.e29. https://doi.org/10.1016/j.cell.2021.04.048.

Hardy, K.M., Garriock, R.J., Yatskievych, T.A., D’Agostino, S.L., Antin, P.B., j.cell.2021.04.048.

Love, M.I., Huber, W., and Anders, S. (2014). Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550. https://doi.org/10.1186/s13059-014-0550-8.

Mikels, A.J., and Nusse, R. (2006). Purified Wnt5a protein activates or inhibits beta-catenin-TCF signaling depending on receptor context. PLoS Biol. 4, e115. https://doi.org/10.1371/journal.pbio.0040115.

Miller, A.J., Dye, B.R., Ferrer-Torres, D., Hill, D.R., Overeem, A.W., Shea, L.D., and Spence, J.R. (2019). Generation of lung organoids from human pluripotent stem cells in vitro. Nat. Protoc. 14, 518–540. https://doi.org/10.1038/s41596-018-0104-8.

Mulay, A., Konda, B., Garcia, G., Jr., Yao, C., Beil, S., Villaiba, J.M., Koziol, C., Sen, C., Purkayastha, A., Kolls, J.K., et al. (2021). SARS-CoV-2 infection of primary human lung epithelium for COVID-19 modeling and drug discovery. Cell Rep. 35, 109055. https://doi.org/10.1016/j.celrep.2021.109055.

Nabhan, A.N., Brownfield, D.G., Harbury, P.B., Krasnow, M.A., and Desai, T.J. (2018). Single-cell Wnt signaling niches maintain stemness of alveolar type 2 cells. Science 359, 1118–1123. https://doi.org/10.1126/science.aam6603.

Park, J., Ivey, M.J., Deana, Y., Riggbskee, K.L., Sörensen, E., Schwabl, V., Sjöberg, C., Hjertberg, T., Park, G.Y., Swonger, J.M., et al. (2019). The Tcf21 lineage constitutes the lung lipofibroblast population. Am. J. Physiol. Lung Cell Mol. Physiol. 316, L872–L885. https://doi.org/10.1152/ajplung.00254.2018.

Sone, N., Konishi, S., Igura, K., Tamai, K., Ikeo, S., Korogi, Y., Kanagaki, S., Namba, T., Yamamoto, Y., Xu, Y., et al. (2021). Multicellular modeling of ciliated airway organoids from human pluripotent stem cells in vitro. Dev. Cell 57, 394–403. https://doi.org/10.1016/j.stemcr.2021.05.010.

Zacharias, W.J., Frank, J.A., Morley, M.P., Alkhaleel, F.A., Kolls, J.F., Zhou, S., Cantu, E., and Morrisey, E.E. (2018). Regeneration of the lung alveolus by an evolutionarily conserved epithelial progenitor. Nature 555, 251–255. https://doi.org/10.1038/nature25786.

Yeo, S.Y., Lee, K.W., Shin, D., An, S., Cho, K.H., and Kim, S.H. (2018). A positive feedback loop bi-stably activates fibroblasts. Nat. Commun. 9, 3016. https://doi.org/10.1038/s41467-018-05274-6.

Zellers, W., Frank, D.B., Zepp, J.A., Morley, M.P., Alkhaleel, F.A., Kolls, J.F., Zhou, S., Cantu, E., and Morrisey, E.E. (2018). Generation of the lung alveolus by an evolutionarily conserved epithelial progenitor. Nature 555, 251–255. https://doi.org/10.1038/nature25786.
### KEY RESOURCES TABLE

| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---------------------|--------|------------|
| Antibodies          |        |            |
| Anti-T-Alexa Fluor 488 | RD systems | Cat# IC2085G; RRID: not listed. |
| Anti-NCAM-Alexa Fluor 647 | BioLegend | Cat# 362513; RRID: AB_2564086 |
| Anti-PDGFRα-Alexa Fluor 647 | BD Biosciences | Cat# 562798; RRID: AB_2737803 |
| Anti-KDR-BV421 | BioLegend | Cat# 393009; RRID: AB_2832739 |
| Anti-Vimentin-Alexa Fluor 647 | Novus Biologicals | Cat# NB1-97670AF647; RRID: not listed. |
| Anti-CD90-BV421 | BioLegend | Cat# 328121; RRID: AB_10933261 |
| Anti-NANOG-Alexa Fluor 488 | BD Biosciences | Cat# 560791; RRID: AB_1937305 |
| Anti-OCT3/4-Alexa Fluor 647 | BD Biosciences | Cat# 560329; RRID: AB_1645318 |
| Anti-FOX2A-PE | BD Biosciences | Cat# 561589; RRID: AB_10716057 |
| Anti-SOX17-Alexa Fluor 647 | BD Biosciences | Cat# 562594; RRID: AB_2737670 |
| Anti-Nestin-BV421 | BioLegend | Cat# 656808; RRID: AB_2566634 |
| Anti-PAX6-Alexa Fluor 488 | BD Biosciences | Cat# 561664; RRID: AB_10895587 |
| Anti-EP CAM-FITC | Miltenyi Biotec | Cat# 130-080-301; RRID: AB_244192 |
| Anti-EP CAM-APC | Miltenyi Biotec | Cat# 130-113-260; RRID: AB_2726061 |
| Anti-EP CAM-BV421 | BD Biosciences | Cat# 563180; RRID: AB_2738050 |
| Isotype control mouse IgG2a-Alexa Fluor 647 | BioLegend | Cat# 400239; RRID: not listed. |
| Isotype control mouse IgG1-BV421 | BioLegend | Cat# 400157; RRID: AB_10897939 |
| Isotype control mouse IgG1-Alexa Fluor 647 | BioLegend | Cat# 400139; RRID: AB_2800436 |
| Isotype control mouse IgG1-Alexa Fluor 488 | BioLegend | Cat# 400132; RRID: not listed. |
| Propidium Iodide | Nacalai tesque | Cat# 29037–76 |
| Anti-EPCAM | Santa Cruz Biotechnology | Cat# sc-66020/EBA-1; RRID: AB_2088654 |
| Anti-mouse IgG-MicroBeads | Miltenyi Biotec | Cat# 130-048-401; RRID: AB_244360 |
| Anti-CPM | Wako | Cat# 014–27501; RRID: AB_2801482 |
| Anti-mouse IgG Alexa Fluor 647 | Thermo Fisher Scientific | Cat# A-31571; RRID: AB_162542 |
| Anti-E-Cadherin | eBioscence | Cat# 14–3249; RRID: AB_1210459 |
| Anti-Vimentin | CST | Cat# 49636; RRID: AB_2793963 |
| Anti-FOXF1 | RD systems | Cat# AF4798; RRID: AB_2105588 |
| Anti-ProSPC | Seven Hills | Cat# WRAB-9337; RRID: AB_2335890 |
| Anti-pro and mature SPB | Abcam | Cat# ab40876; RRID: AB_778186 |
| Anti-matureSPC | Seven Hills | Cat# WRAB-76694; RRID: not listed. |
| Anti-ABCA3 | Seven Hills | Cat# WMAB-17G524; RRID: not listed. |
| Anti-HT1-56 | Terrace | Cat# TB-29AHT1-56; RRID: AB_2847898 |
| Anti-PDPN-APC | eBioscence | Cat# 17-9381-42; RRID: AB_10801951 |
| Anti-GFP | Aves Labs | Cat# GFP-1020; RRID: AB_10000240 |
| Anti-EP CAM | RD systems | Cat# AF960; RRID: AB_357545 |
| Anti-Influenza A H3N2 NP | Sino Biological | Cat# 40208-RP01; RRID: not listed. |
| Anti-SARS-CoV/SARS-CoV-2 NP | GeneTex | Cat# GTX632269; RRID: AB_2888304 |
| Anti-MX1 | RD systems | Cat# AF7946; RRID: not listed. |
| Anti-NaPi2b | kindly provided by Dr. Gerd Ritter (MX35) | N/A |
| Anti-rat IgG Alexa Fluor 488 | Thermo Fisher Scientific | Cat# A-21208; RRID: AB_2535794 |

(Continued on next page)
### REAGENT or RESOURCE SOURCE IDENTIFIER

| REAGENT or RESOURCE | SOURCE                           | IDENTIFIER    |
|---------------------|----------------------------------|---------------|
| Anti-mouse IgG Alexa Fluor 546 | Thermo Fisher Scientific | Cat# A-10036; RRID: AB_2534012 |
| Anti-goat IgG Alexa Fluor 647 | Thermo Fisher Scientific | Cat# A-21447; RRID: AB_2535864 |
| Anti-rabbit IgG Alexa Fluor 647 | Thermo Fisher Scientific | Cat# A-31573; RRID: AB_2536183 |
| Anti-chicken IgY Alexa Fluor 488 | Jackson ImmunoResearch | Cat# 703-546-155; RRID: AB_2340376 |
| Anti-rabbit IgG Cy3 | Jackson ImmunoResearch | Cat# 711-165-152; RRID: AB_2307443 |
| Anti-mouse IgG Alexa Fluor 488 | Thermo Fisher Scientific | Cat# A-21202; RRID: AB_141607 |
| Anti-mouse IgG1 Cy3 | Jackson ImmunoResearch | Cat# 115-165-205; RRID: AB_2338694 |

### Bacterial and virus strains

| Bacterial and virus strains | SOURCE                           | IDENTIFIER    |
|----------------------------|----------------------------------|---------------|
| Influenza A H1N1 A/Narita/1/2009 | National institute of infectious diseases | N/A |
| SARS-CoV-2 WK521 | National institute of infectious diseases | N/A |

### Biological samples

| Biological samples | SOURCE                           |
|--------------------|----------------------------------|
| PBS                | Nacalai tesque                   |
| Geltrex            | Thermo Fisher Scientific         |
| iMatrix-511 silk   | Nippi                            |
| Matrigel Growth Factor Reduced Basement Membrane Matrix | Corning |
| Essential 8        | Thermo Scientific                |
| STEMdiff™ Trilineage Differentiation Kit | STEMCELL |
| mTeSR plus         | STEMCELL                         |
| Penicillin-streptomycin | Thermo Fisher Scientific       |
| Y-27632            | LCL laboratories                 |
| StemPro™-34        | Thermo Fisher Scientific         |
| Glutamax           | Thermo Scientific                |
| ActivinA           | API                              |
| BMP4               | RD systems                       |
| CHIR99021          | AXON Medchem                     |
| KGF                | Peprotech                        |
| bFGF               | KAC                              |
| FGF10              | Peprotech                        |
| RPMI 1640          | Nacalai tesque                   |
| DMEM/F12 plus Glutamax | Thermo Fisher Scientific      |
| Ham’s F12          | Wako                            |
| DMEM with high glucose | Nichirei              |
| Fetal bovine serum | Nacalai tesque                   |
| B27 supplement     | Thermo Fisher Scientific         |
| L-ascorbic acid    | Sigma                           |
| Monothioglycerol   | Wako                            |
| Bovine Serum Albumin Fraction V Solution (7.5%) | Thermo Fisher Scientific |
| HEPES 1M solution  | Life Sciences                    |
| CaCl2              | Wako                            |
| ITS premix         | Corning                         |
| Dexamethasone      | Sigma-Aldrich                    |
| IBMX               | Wako                            |
| 8-Br-cAMP          | LIFE SCIENCE INSTITUTE           |

(Continued on next page)
| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---------------------|--------|------------|
| R-spondin 2         | RD systems | 3266-RS-025/CF |
| R-spondin 3         | RD systems | 3500-RS-025/CF |
| FST                 | RD systems | 4889-FN-025/CF |
| FSTL1               | RD systems | 1694-FN-050  |
| FSTL3               | RD systems | 1288-F3-025/CF |
| DCN                 | RD systems | 143-DE-100   |
| Sodium butyrate     | Wako    | 193-01522   |
| SB431542            | Wako    | 198-16543   |
| Noggin              | RD systems | 6057-NG-01M |
| Retinoic acid       | Sigma-Aldrich | R2625 |
| DAPT                | Wako    | 049-33583   |

**Critical commercial assays**

| Fixation and Permeabilization Solution | BD Biosciences | 554722 |
| Perm/Wash Buffer                    | BD Biosciences | 554723 |
| PureLink RNA mini kit               | Thermo Fisher Scientific | 12183020 |
| Rneasy micro kit                    | Qiagen         | 74004  |
| RNaseOUT™ Recombinant Ribonuclease Inhibitor | Thermo Fisher Scientific | 10777019 |
| SuperScript™ III Reverse Transcriptase | Thermo Fisher Scientific | 18080044 |
| Power SYBR Green PCR Master Mix     | Thermo Fisher Scientific | 4368708 |
| Human iPS Cell Generation™ Episomal Vector Mix | Takara | 3673 |

**Chromium Next GEM**

| Chromium Next GEM Single Cell 3’ GEM, Library & Gel Bead Kit v3.1 | 10 x Genomics | PN-1000128 |
| Chromium Next GEM Single Cell 3’ Kit v3.1 | 10 x Genomics | PN-1000269 |
| Chromium Next GEM Chip G Single Cell Kit | 10 x Genomics | PN-1000127 |
| Single Index Kit T Set A | 10 x Genomics | PN-1000213 |
| Dual Index Kit TT Set A | 10 x Genomics | PN-1000215 |

**Deposited data**

| Bulk RNA-seq data | This paper | Access number GEO:188822 |
| scRNA-seq data    | This paper | Access number GEO:188823 |

**Experimental models: Cell lines**

| Human healthy donor iPSC line (201B7) | Takahashi et al. | https://www.cira.kyoto-u.ac.jp |
| 201B7 iPSC line targeted with SFTPC-GFP (B2-3) | Gotoh Lab | Gotoh Lab |
| Human normal donor iPSC line (604A1) | Okita et al. | https://www.cira.kyoto-u.ac.jp |
| HFLF | DV Biologics | PP002-F-1349 (Discontinued) |
| HDF (TIG120) | Kondo et al. | https://cellbank.nibiohn.go.jp |
| HFLF iPSC (HFA) | This paper | N/A |
| HDF (TIG120) iPSC (GC23) | This paper | N/A |
| MDCK | National institute of infectious diseases | N/A |
| VeroE6/TMPRSS2 | National institute of infectious diseases | N/A |

**Oligonucleotides**

| Primers for qRT-PCR are listed in Table S3 | N/A | N/A |

**Software and algorithms**

| FlowJo                  | FlowJo, LLC | N/A |
| FIJI                    | N/A | https://imagej.net |
| Prism 9 for Mac OSX    | GraphPad   | N/A |

(Continued on next page)
RESOURCE AVAILABILITY

Lead contact
Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Shimpei Gotoh (gotoh.shimpei.5m@kyoto-u.ac.jp).

Materials availability
201B7 and 604A1 were obtained from CiRA at Kyoto University. TIG120 was obtained from JCRB (JCRB0542). B2-3, HFA and GC23 are available from the lead contact upon request. HFLF has been discontinued (DV Biologics) but is available from the lead contact upon request for use in academia.

Data and code availability
- Bulk RNA (GSE188822) and single-cell RNA-seq data (GSE188823) have been deposited in the NCBI Gene Expression Omnibus.
- This paper does not report original code.
- Additional Supplemental Items are available from Mendeley Data: http://dx.doi.org/10.17632/6pgb6rx8t8.1.
- Any additional information required to reanalyze the data reported in this paper is available from the lead contact upon request.

EXPERIMENTAL MODEL AND SUBJECT DETAILS

Generation of human iPSCs
HFLF-iPSCs (HFA) were established from HFLF (17.5 weeks of gestation; DV Biologics; PP002-F-1349, lot 121109VA). HFLF (1 × 10^6 cells) were transfected with human iPSC generation episomal vector mix containing cDNA of OCT3/4, SOX2, KLF4, LIN28, mp53-DD, and EBNA1 (Takara, 3673). Transfected cells (5 × 10^5 cells) were seeded on a well of a 6-well plate with 10% fetal bovine

---

RESOURCE AVAILABILITY

| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---------------------|--------|------------|
| fastp 0.20.1        | N/A    | https://github.com/OpenGene/fastp#install-with-bioconda |
| SortMeRna 2.1b      | N/A    | https://github.com/biocore/sortmerna |
| STAR 2.7.6a         | N/A    | https://github.com/alexdobin/STAR |
| RSEM 1.3.3          | N/A    | https://github.com/deweylab/RSEM |
| R 4.1.1             | CRAN   | http://www.R-project.org |
| tximport 1.20.0     | N/A    | https://github.com/mikelove/tximport |
| DESeq2 1.32.0       | N/A    | https://github.com/mikelove/DESeq2 |
| clusterProfiler 4.0.5 | N/A | https://github.com/YuLab-SMU/clusterProfiler |
| org.Hs.eg.db 3.13.0 | N/A    | https://anaconda.org/bioconda/bioconductor-org.hs.eg.db |
| Cell Ranger 4.0.0   | 10x Genomics | https://www.10xgenomics.com |
| Seurat 4.0.3        | N/A    | https://github.com/satijalab/seurat |
| r-plotly 4.9.4.1    | N/A    | https://anaconda.org/conda-forge/r-plotly |
| **Other**           |        |            |
| Accutase            | Innovative Cell Technologies | #AT-104-500 |
| 2.5g/L-Trypsin/1mmol/L-EDTA Solution | Nacalai tesque | 32777–15 |
| TrypLE Select Enzyme (1X) | Thermo Fisher Scientific | 12563029 |
| DispaseII           | Wako   | 383–02281 |
| Cell Culture Insert 0.4μm pore size 24well format | Corning | 353095 |
| Cell Culture Insert 0.4μm pore size 12well format | Corning | 353180 |
| MACS LS column      | Miltenyi Biotec | 130-042-401 |
| MACS LD column      | Miltenyi Biotec | 130-042-901 |
| Eplasia 96-well plate | Corning | 4446 |
| Poly(2-hydroxyethyl methacrylate) | Sigma-Aldrich | 192066 |
| Donkey Serum        | EMD-Millipore | S30-100ML |
Biotechnology, sc-66020/EBA-1) by incubating the cells in the antibody solution at 1 RPMI1640 (Nacalai Tesque, 30264–56) containing 100 ng/mL activin A, as previously described (Gotoh et al., 2014; Konishi et al., 2016; Yamae et al., 2017). In brief, undifferentiated human iPSCs were differentiated into definitive endodermal cells on Geltrex-coated plates.

Human iPSCs were differentiated into lung progenitor cells, as previously described (Gotoh et al., 2014; Konishi et al., 2016; Yamae et al., 2017). Undifferentiated human iPSCs were washed in D-PBS and incubated in Accutase (Innovative Cell Technologies, AT-104) at 37 °C for 20 min to dissociate the cells into single cells. After neutralizing Accutase by adding one volume of mTeSR Plus, the cells were centrifuged with a mini centrifuge for 1 min. The generated iPSC colonies were picked up and replated to a 24-well plate with StemFit AK02N and iMatrix-511 silk (Nippi, 892021) (0.25 g/cm2). The generated iPSC colonies were maintained in StemFit AK02N. The medium was switched to mTeSR Plus (STEMCELL Technologies, ST-05825 or ST-100-0276) after several passages, and then used for subsequent differentiation experiments. HDF-iPSCs (GC23) were established from HDF (TIG120) in a feeder-dependent manner by using episomal vectors (OCT3/4, SOX2, KLF4, L-MYC, LIN28, short hairpin RNA for p53), as described previously (Korogi et al., 2019). After expansion and stocking, HDF-iPSCs were maintained in a feeder-free manner with mTeSR Plus medium prior to differentiation. Trilineage differentiation of HFA- and GC23-iPSCs into endoderm, mesoderm, and ectoderm was validated using a STEMdiff™ Trilineage Differentiation kit (STEMCELL, ST-05230), according to the manufacturer’s protocol.

### Maintenance of iPSCs
Stock vials of SFTPC-GFP reporter iPSCs (B2-3), 201B7, or 604A1 were thawed with the prewarmed Essential 8 medium (Thermo Fischer Scientific, A1517001). Cell suspensions were centrifuged with a mini centrifuge for 1 min. Cells were resuspended in 4 mL of Essential 8 medium supplemented with 10 μM Y27632 and 50 U/mL penicillin/streptomycin (ThermoFisher, 15140–163) were seeded onto a 6-well plate at a density of 8–15 × 104 cells/well in mTeSR Plus medium containing iMatrix-511 silk (0.25 μg/cm2) and 10 μM CHIR99021 (Axon Medchem, Axon1386) as an activator of canonical Wnt signaling, Glutamax (Thermo Fischer Scientific, 35050-606), and 50 U/mL penicillin/streptomycin (Table S1), and the medium was replaced on day 2. On day 3, the medium was switched to StemPro™-34 supplemented with 3 ng/mL Activin A, 10 ng/mL KGF (Prospec, CYT-219), 25 ng/mL BMP4, 10 ng/mL bFGF (DS Pharma Biomedical, KHFGF001), 10 ng/mL FGF10 (Peprotech, 100-26), Glutamax (×100), and 50 U/mL penicillin/streptomycin and replaced on day 5. On day 7, the cells were detached with TrypLE Select Enzyme (Thermo Fischer Scientific, 12563029) at 37 °C for 10 min. The single-cell suspension was washed with 2% FBS/DMEM and labeled with anti-EPCAM antibody (Santa Cruz Biotechnology, sc-66020/EB/A-1) by incubating the cells in the antibody solution at 1 μL in 100 μL of 1% bovine serum albumin (BSA)/PBS per million cells at 25 °C for 20 min. Then, EPCAM− cells were negatively isolated by Magnetic-activated cell sorting (MACS) using anti-mouse IgG microbeads (Miltenyi Biotec, 130-048-401) as the secondary antibody and an LD column (Miltenyi Biotec, 130-048-401), according to the manufacturer’s instructions. The recovered mesenchymal cells were used as the iMES.

### Induction of IMES
Undifferentiated human iPSCs were washed in D-PBS and incubated in Accutase (Innovative Cell Technologies, AT-104) at 37 °C for 30 min to dissociate the cells into single cells. After neutralizing Accutase by adding one volume of mTeSR Plus, the cells were centrifuged with a mini centrifuge for 1 min. The recovered single-cell suspension was seeded onto a 6-well plate at a density of 8–15 × 104 cells/well in mTeSR Plus medium containing iMatrix-511 silk (0.25 μg/cm2) and 10 μM CHIR99021 (Axon Medchem, Axon1386) as an activator of canonical Wnt signaling, Glutamax (Thermo Fischer Scientific, 35050-606), and 50 U/mL penicillin/streptomycin (Table S1), and the medium was replaced on day 2. On day 3, the medium was switched to StemPro™-34 supplemented with 3 ng/mL Activin A, 10 ng/mL KGF (Prospec, CYT-219), 25 ng/mL BMP4, 10 ng/mL bFGF (DS Pharma Biomedical, KHFGF001), 10 ng/mL FGF10 (Peprotech, 100-26), Glutamax (×100), and 50 U/mL penicillin/streptomycin and replaced on day 5. On day 7, the cells were detached with TrypLE Select Enzyme (Thermo Fischer Scientific, 12563029) at 37 °C for 10 min. The single-cell suspension was washed with 2% FBS/DMEM and labeled with anti-EPCAM antibody (Santa Cruz Biotechnology, sc-66020/EB/A-1) by incubating the cells in the antibody solution at 1 μL in 100 μL of 1% bovine serum albumin (BSA)/PBS per million cells at 25 °C for 20 min. Then, EPCAM− cells were negatively isolated by Magnetic-activated cell sorting (MACS) using anti-mouse IgG microbeads (Miltenyi Biotec, 130-048-401) as the secondary antibody and an LD column (Miltenyi Biotec, 130-048-401), according to the manufacturer’s instructions. The recovered mesenchymal cells were used as the iMES.

### Induction of NKX2-1+ lung progenitor cells
Human iPSCs were differentiated into lung progenitor cells, as previously described (Gotoh et al., 2014; Konishi et al., 2016; Yamamoto et al., 2017). In brief, undifferentiated human iPSCs were differentiated into definitive endodermal cells on Geltrex-coated plates in RPMI1640 (Nacalai Tesque, 30264–56) containing 100 ng/mL activin A, 1 μM CHIR99021, 2% B27 supplement (ThermoFisher, 17504–001), and 50 U/mL penicillin/streptomycin. The medium was replaced every two days. Y-27632 was supplemented on day 1, and sodium butyrate (Wako, 193–01522) was added on days 1, 2, and 4. During days 6–10, the definitive endodermal cells were cultured in the anteriorization medium, followed by switching to the ventralization medium containing CHIR99021 (3 μM), BMP4 (20 ng/mL) and adjusted doses of ATRA (Sigma-Aldrich, R2625) (Table S2) on day 10. The optimized concentration of ATRA for B2-3 iPSCs was 0.05–0.5 μM. During days 14–21, the cells were cultured in CFKD preconditioning medium (Table S2). On day 21, NKX2-1+ lung progenitor cells were isolated using mouse anti-human CPM (Wako, 014–27501) and anti-mouse IgG-Algexa647 (Thermo Fischer Scientific, A-31571) to gate CPMhigh cells, as previously reported (Yamamoto et al., 2017). The antibodies used are listed in KEY RESOURCES TABLE.

### AOs formation in a 3D culture and passage of SFTPC* cells
AOs were generated as previously described (Korogi et al., 2019; Yamamoto et al., 2017). A total of 1.0 × 106 CPMhigh cells and 5.0 × 105 HFLF, TIG120 or IMES were mixed in 100 μL of the alveolarization medium (Table S2) supplemented with Y-27632 (10 μM) and 100 μL of Matrigel (Corning, 354230) and placed on a 12-well cell culture insert (Corning, 353180). The medium in the
lower chamber was changed every two days. HFLF were cultured in DMEM (Nacalai Tesque, 08459–64) supplemented with 10% FBS and used at 10 passages. TIG120 cells were cultured in MEM medium (Nacalai Tesque, 21442–25) supplemented with 10% FBS and used within 30 PDL. The whole gels containing AOs were collected in a 15 mL tube and 0.1% Trypsin-EDTA was added. Fragmented gels were gently pipetted and incubated at 37 °C for 6 min. Samples were gently resuspended and incubated at 37 °C for an additional 10 min. After neutralizing 0.1% Trypsin-EDTA by 2%FBS, samples were washed twice in 1% BSA/PBS, and immunostained with anti-EPCAM-APC (Miltenyi Biotec, 130-113-263) antibodies. SFTPC-GFP+/EPCAM+ cells were recovered using flow cytometry. For passage culture, a total of 1.0 × 10^6 SFTPC-GFP+/EPCAM+ cells and 5.0 × 10^5 iMES were mixed in 100 µL of the alveolarization medium supplemented with Y-27632 (10 µM) and 100 µL of Matrigel and placed on a 12-well cell culture insert. Passage was performed every 2 weeks. The antibodies used are shown in KEY RESOURCES TABLE.

**Validation study of canonical Wnt ligands and TGFβ-inhibitors using fibroblast-free AOs**

CPM+ lung progenitor cells on day 21 were isolated by MACS using anti-mouse IgG microbeads as the secondary antibody and an LS column (Miltenyi Biotec, 130-042-401), according to the manufacturer’s instructions. A total of 2.0 × 10^6 of CPM+ lung progenitor cells were suspended in 200 µL of alveolarization medium supplemented with each factor (10 µM Y-27632, 3 µM CHIR99021, 200 ng/mL RSPO2 (RD systems, 3266-BS-025/CF), 200 ng/mL RSPO3 (RD systems, 3500-BS-025/CF), 10 µM SB431542 (Wako, 198-16543) as an inhibitor of TGF-β signaling, 200 ng/mL FST (RD systems, 4889-025/CF), 200 ng/mL FSTL1 (RD systems, 1694-FN-050), 200 ng/mL FSTL3 (RD systems, 1288-F3-025/CF), and 200 ng/mL DCN (RD systems, 143-DE-100)) and seeded onto 96 well plates (Corning, 4446) coated with poly-(2-hydroxyethyl methacrylate) (Sigma-Aldrich, 192066) to form cell aggregates. The cell aggregates were centrifuged with a mini centrifuge for 1 min after incubation for 24 h at 37 °C and 5% CO2. The cell aggregate pellets were gently resuspended in 20 µL of pre-cooled Matrigel and placed into a well of a 24-well cell culture plate (Greiner Bio-One, 662160). After incubation for 20 min at 37 °C, 500 µL of alveolarization medium supplemented with each factor was added to the Matrigel-embedded cell aggregates and replaced every two days. On day 5, cells were dissociated with 0.1% trypsin-EDTA at 37 °C for 15 min. After neutralizing 0.1% Trypsin-EDTA by 2%FBS, samples were washed twice in 1% BSA/PBS and immunostained with anti-EPCAM-APC antibodies. The ratio of SFTPC-GFP+/EPCAM+ cells in each condition was evaluated using flow cytometry.

**Viruses**

Influenza A virus A/JP/Narita/1/2009 (H1N1; National Institute of Infectious Diseases) was propagated in MDCK cells with trypsin. MDCK cells were cultured in DMEM. The medium was centrifuged at 1400 g for 10 min, and the supernatant was stored at −80 °C. The SARS-CoV-2 strain WK-521 (National Institute of Infectious Diseases) was grown in VeroE6 cells expressing human transmembrane serine protease TMPRSS2 (VeroE6/TMPRSS2; JCRB Cell Bank). VeroE6/TMPRSS2 cells were cultured for virus propagation in DMEM supplemented with 2% FBS and 1 mg/mL G418 (Roche, 4727878001). The supernatant recovered from inoculation culture was centrifuged at 1400 × g for 10 min, and the supernatant was stored at −80 °C. All work with SARS-CoV-2 was performed in the biosafety level 3 facility of the National Institute of Infectious Diseases and Kitasato University.

**Direct infection of influenza A and SARS-CoV-2 viruses of matrigel-embedded organoids**

iMES-AOs at P2, consisting of alveolar epithelial cells differentiated from an SFTPC-GFP reporter iPSC line (B2-3) and HFLF-iMES, were mixed in 50 µL of the alveolarization medium supplemented with Y-27632 (10 µM) and 50 µL of Matrigel, and then placed on a 24-well cell culture insert (Corning, 353095) on day 0. On day 12, each viral solution of influenza A H1N1 A/Narita/1/2009 or SARS-CoV-2 was added to the medium of the upper and lower chambers at 10^3 PFU for virus infection. The virus was added to Matrigel without cells and evaluated as a negative control for viral titer measurements. Non-infected controls were prepared for IF staining. iMES-AOs were cultured at 37 °C and 5% CO2. Three days post-infection, whole gels were collected for viral titer measurement and IF staining.

**SARS-CoV-2 WK-521 infection post organoid dissociation**

Prior to infection, 500 µg/mL Dispase II (Wako, 383–02281) was added to the upper and lower chambers and incubated for 1 h at 37 °C to mildly disolve iMES-AOs-embedded Matrigel. Whole gels were collected, gently suspended, and washed three times with 1% BSA/PBS. Then, the cells were mixed with the viral solution of SARS-CoV-2 with 10^5 PFU in 100 µL and incubated at 37 °C for 2 h. After washing three times, cells were suspended in 50 µL alveolarization medium, mixed with an equal volume of Matrigel, and seeded onto a cell culture insert of 24-well format. iMES-AOs were cultured at 37 °C and 5% CO2. Three days post-infection, whole gels were collected for virus titration and IF staining.

**Flow cytometry**

The single-cell suspension was washed with 1% BSA/PBS and immunostained with primary antibodies at 4 °C for 15 min. After being washed twice with 1% BSA/PBS, the cells were stained with secondary antibodies at 4 °C for 15 min. After being washed twice with 1% BSA/PBS, the cells were stained with propidium iodide (Nacalai Tesque, 29037–76). For intracellular staining, single-cell suspensions were fixed by fixation and permeabilization solution (BD Biosciences, 554722) at 25 °C for 20 min. After washing twice with Perm/Wash Buffer (BD Biosciences, 554723), the cells were immunostained with primary antibodies at 4 °C for 30 min. After washing...
twice with Perm/Wash Buffer, the cells were stained with secondary antibodies at 4°C for 30 min. After washing twice with 1% BSA/PBS, the cells were prepared in 1% BSA/PBS without propidium iodide for flow cytometry analysis using Melody (BD Biosciences). The antibodies used are listed in KEY RESOURCES TABLE.

RNA-seq analysis
Total RNA was extracted using an RNeasy Micro kit (Qiagen, 74004) according to the manufacturer’s protocol. The libraries were prepared using the TruSeq Stranded mRNA Library Prep kit (Illumina), then they were sequenced using a NovaSeq 6000 (Illumina) platform with 100-bp paired-end reads. FASTQ raw data were trimmed using fastp 0.20.1 (Chen et al., 2018) and then rRNA, tRNA, snRNA, snoRNA, Mt_rRNA, and Mt_tRNA were excluded using SortMeRna 2.1b (Kopylova et al., 2012). They were aligned to GRCh38 using STAR 2.7.6a (Dobin et al., 2013). Read counts and transcripts per million (TPM) were calculated using RSEM 1.3.3 (Li and Dewey, 2011). The data were imported to R 4.1.1 using tximport 1.20.0 (Soneson et al., 2015), and low-expression genes with average read counts among the data set samples under 1 were excluded for downstream analyses. DESeq2 1.32.0 (Love et al., 2014) was used to identify DEGs. Enrichment analysis for GO of biological processes was performed using clusterProfiler 4.0.5 (Wu et al., 2021) and org.Hs.eg.db 3.13.0.

scRNA-seq analysis
A single-cell preparation was performed via enzymatic dissociation. Whole gels were gently suspended in 0.1% Trypsin-EDTA. Fragmented gels were gently pipetted and incubated at 37°C for 6 min. Samples were suspended gently again and incubated at 37°C for 10 min, washed in alveolarization medium containing 10 μM Y-27632 twice, and filtered through a 40-μm strainer. Single-cell RNA libraries were prepared using a 10x Genomics Chromium device according to the manufacturer’s protocols (Single Cell 3’ Reagent Kits v3.1). The libraries were sequenced using NovaSeq 6000 (Illumina). Reads were mapped to GRCh38, and count matrices were generated using the Cell Ranger (10x Genomics). Processing of the single-cell data was conducted with Seurat 4.0.5 (Hao et al., 2021). In brief, cells expressing mitochondrial genes accounting for >20% and <1.5% were removed to exclude dead and low-quality cells. In addition, outliers of UMI and expressed genes were also removed to exclude doublet and low-quality cells. Then, the UMI count was normalized using SCTransform. Principal component (PC) analysis (PCA) was conducted using the Seurat function RunPCA and embedded in UMAP using the Seurat function RunUMAP on 20 PCs at a resolution of 0.4 (Figures 3G and 3H). UMAP plots were visualized using Plotly 4.9.4.1, and violin plots were drawn using Seurat. Cell-type definition was performed according to expression of representative genes as follows; clusters 1, 2, 3, 9, and 11 were annotated as epithelial cells based on the high expression of EPAC1. Clusters 5, 6, and 7 were annotated as mitotic epithelial cells based on the high expression of EPAC1, MKI67, and TOP2A. Clusters 0, 4, and 10 were annotated as mesenchymal cells based on the high expression of COL1A1. Clusters 8 was annotated as mitotic mesenchymal cells based on their high expression of COL1A1, MKI67, and TOP2A. The re-clustering of epithelial cells, except for mitotic epithelial cells, was performed. PCA was conducted using the Seurat function RunPCAM and embedded in UMAP using the Seurat function RunUMAP on 25 PCs at a resolution of 0.6 (Figures 3J and 3K). Cell-type definition was performed according to expression of representative genes as follows; clusters 9 and 20 were annotated as iAT1 on the high expression of AGER and CAV1. Clusters 2, 4, 5, 7, 11, and 15 were annotated as iAT2 based on their high expression of SFTPBP and SFTPC. Cluster 23 showed high expression levels of FOXJ1, RSPH1, and SFTPC, indicative of SFTPC⁺ distal tip cells differentiating into ciliary cells. Cluster 21 and 22 were annotated as IPNEC based on their high expression of ASC1L1, SYP and CHGA. The other epithelial clusters were annotated as follows: clusters 1, 3, 6, 8, and 10, CPM/NKX2-1⁺ cells; clusters 0, 12, 14, 17, and 18, ASCL1⁺ cells; clusters 13, 16, and 19, TM4SF1⁺ cells. Re-clustering of mesenchymal cells, except for mitotic mesenchymal cells, was performed. PCA was conducted using the Seurat function RunPCAM and embedded in UMAP using the Seurat function RunUMAP on 15 PCs at a resolution of 0.7 (Figures 3N and 3O). Cell-type definition was performed according to expression of representative genes as follows; clusters 2, 5, 6, 7, 9, 10, 14, 15 and 16, FOXF1⁺ TCF21⁺ cells; clusters 0, 1, 8 and 17, ACTA2⁺FOXF1⁺ TCF21⁺ cells; clusters 11 and 12, PRRX1⁺ FOXF1⁺ TCF21⁺ cells; clusters 3 and 13, CXCL12⁺ FOXF1⁺ TCF21⁺ cells; clusters 4, 18 and 19, IRX3⁺ FOXO1⁺ TCF21⁺ FOXF1⁺ cells.

qRT-PCR
Total RNA was extracted using a PureLink RNA Mini kit (Thermo Fisher Scientific, 12183020). cDNA was prepared from 80 ng of total RNA per sample with SuperScript III reverse transcriptase (Thermo Fisher Scientific, 18080044), amplified using Power SYBR Green PCR Master Mix (Applied Biosystems, 4368708), and quantified using QuantStudio 3 (Applied Biosystems). Gene expression was normalized to β-actin expression levels. The relative gene expression of mesenchymal markers was compared to 201B7 on day 0 (Figure S1A). Exogenous control RNA of human fetal lung at 17, 18, and 22 weeks of gestation was used (Agilent Technologies; #540177, lot 0006055802) to calculate relative AO gene expression (Figures S1D and S3A). The primers used in this study are listed in Table S4.

IF staining
Two-dimensional culture was fixed with 4% paraformaldehyde/PBS at 25°C for 15 min, permeabilized with 0.2% Triton X-100/PBS at 25°C for 15 min, and blocked using PBS containing 5% normal donkey serum (EMD-Millipore, S30-100ML). The samples were then immunostained with primary and secondary antibodies. AOs were fixed with 4% paraformaldehyde/PBS at 25°C for 20 min and
incubated in 30% sucrose/PBS at 4°C overnight. They were then embedded in the OCT compound (Sakura Finetek, 4583) and frozen in liquid nitrogen. The frozen organoids were sliced into 10-μm-thick sections on slides, permeabilized, and blocked as described above. They were then immunostained with primary antibodies overnight and with secondary antibodies for 1 h. Hoechst-33342 (Dojindo, H342) was added to the secondary antibody solution to label the nuclei. The antibodies used in this study are listed in KEY RESOURCES TABLE. Images were captured using a BZ-X710 microscope (Keyence).

Electron microscopy
Whole gels were incubated in a fixative solution consisting of 2.5% glutaraldehyde, 4% paraformaldehyde, 1% tannic acid (Koso Chemical), and 0.1 M phosphate buffer (pH 7.4) at 4°C overnight. The next day, the fixative solution was changed to one without tannic acid. After three washes in 0.1 M phosphate buffer (pH 7.4) for 20 min, the samples were fixed in 1% osmium tetroxide (Nacalai Tesque, 25727–01) for 2 h and gradually dehydrated and embedded in pure epon as previously described (Konishi et al., 2016; Sone et al., 2021). Ultrathin sections were stained with uranyl acetate and lead citrate and analyzed using transmission electron microscopy (JEOL; JEM-1400).

QUANTIFICATION AND STATISTICAL ANALYSIS
All error bars indicate the SEM. The quantified data represent the findings of three or more independent experiments. Statistical analyses of qRT-PCR and flow cytometry were performed using the Prism 9 software program (GraphPad). Multiple comparisons were performed using the Kruskal–Wallis test and post-hoc Dunn’s test. Two-group comparison in Figure 4B was performed using the Mann–Whitney test.